AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RAPP

Ceesay Abraham sold $938K of RAPP

Ceesay Abraham (Chief Executive Officer) sold 18,921 shares of Rapport Therapeutics, Inc. (RAPP) at $49.57 ($0.94M total) on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ceesay Abraham
Published Aug 26, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RAPP
Neutral
medium confidence
Mentioned
$RAPP
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RAPPNeutralLow
01

Why it matters

The disclosed sale is the first public report of this transaction, providing new data for traders.

02

Market read

While the filing is a primary source, the modest size limits its trading relevance.

03

What to watch

The CEO's remaining stake remains sizable, and the 10b5-1 plan suggests pre‑planned execution.

Relevance 4/10Novelty 4/10Timing: post‑market 2026-08-26 filing

Background

Form 4 filings disclose insider transactions; investors monitor them for signals of insider confidence.

Company-level read

Ticker impact

$RAPPNeutralMedium confidence
Context

CEO Ceesay Abraham sold 18,921 shares for $938K via a 10b5-1 plan, reducing his stake to 467,187 shares.

Expected impact

Potential slight downward pressure in the near term, likely within a few cents.

Evidence & confidence

A sub‑$1M sale by the CEO is disclosed for the first time, but the scale is modest and unlikely to move the stock dramatically.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are routine.

Regional

No regional effect beyond the company's own share price.

Global

Limited global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event rather than a lack of confidence.

Key entities

  • Company
    Rapport Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker RAPP.

  • Executive
    Ceesay Abraham

    Chief Executive Officer of Rapport Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RAPP insider trading history →

Related articles

$RAPPMed

Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary

Rapport Therapeutics reported no revenue and a net loss of $40.2M in 3Q 2026, widening from a $26.9M loss in the prior-year quarter. Diluted EPS was $(0.84). The company began Phase 3 trials for RAP-219 in epilepsy and plans further trials in 2027. Collaboration revenue from Tenacia was $20M for the nine months. According to the company, they deferred one program and prioritized another.

tradingview.com
$RAPPHighAI 9/10

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label

SEC EDGAR 8-K
$RAPPMedAI 9/10

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Therapeutics (RAPP) closed public offerings of 9.76M shares of common stock at $21.00 per share, $172.5M in convertible notes, and a concurrent private placement of 1.43M shares. Total net proceeds are approximately $410.7M. Proceeds will fund clinical trials, R&D, and general corporate purposes. The notes have a 2.25% interest rate and mature in 2032.

finance.yahoo.com